会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Apparatus for generating biphasic waveforms in an implantable
defibrillator
    • 用于在可植入除颤器中产生双相波形的装置
    • US5871505A
    • 1999-02-16
    • US457307
    • 1995-06-01
    • Theodore P. AdamsMark W. Kroll
    • Theodore P. AdamsMark W. Kroll
    • A61N1/39
    • A61N1/3956A61N1/3906A61N1/3912
    • A method and apparatus for generating biphasic waveforms for an implantable defibrillator uses two disparate capacitor systems. A first phase of the biphasic waveform is generated from the charge stored in a first capacitor system, and a second phase of less energy than the first phase is generated from the charge stored in a second capacitor system. By using a second capacitor system for the second phase of the biphasic waveform that stores less energy than the first capacitor system, the overall size and power requirements of the implantable device can be reduced. In a preferred embodiment, the disparate capacitor systems have different effective capacitances, with the second capacitor system preferably having a higher effective capacitance, but a lower charging voltage, than the first capacitor system.
    • 用于产生可植入除颤器的双相波形的方法和装置使用两个不同的电容器系统。 从存储在第一电容器系统中的电荷产生双相波形的第一相,并且从存储在第二电容器系统中的电荷产生比第一相少的能量的第二相。 通过使用存储比第一电容器系统更少的能量的双相波形的第二相的第二电容器系统,可以减小可植入装置的总体尺寸和功率要求。 在优选实施例中,不同的电容器系统具有不同的有效电容,其中第二电容器系统优选地具有比第一电容器系统更高的有效电容,但是具有较低的充电电压。
    • 3. 发明授权
    • Neuro-stimulation to control pain during cardioversion defibrillation
    • 神经刺激以控制心脏复律除颤期间的疼痛
    • US5792187A
    • 1998-08-11
    • US480938
    • 1995-10-05
    • Theodore P. Adams
    • Theodore P. Adams
    • A61N1/34A61N1/39
    • A61N1/3962A61N1/36071
    • A system and method for reducing the perceived pain by a patient occurring during cardioversion/defibrillation countershocks to the heart. The system comprises an electrode subsystem for positioning at least one electrode in contact with a patient, a pain reducing stimulation subsystem for providing pain reducing electromagnetic stimulation to the electrode subsystem, a cardioversion/defibrillation countershock subsystem for treatment of cardiac fibrillation, and a control subsystem. The control subsystem provides synchronization of the pain reducing stimulation subsystem with the cardioversion/defibrillation countershock subsystem so that delivery of pain reducing stimulation to the patient begins prior to a cardioversion/defibrillation countershock.
    • 用于减少心脏复发/除颤期间发生心脏感觉到的疼痛的系统和方法。 该系统包括用于定位与患者接触的至少一个电极的电极子系统,用于向电极子系统提供疼痛减轻电磁刺激的减轻疼痛的子系统,用于治疗心脏纤维性颤动的复律/除颤抗倒伏子系统以及控制子系统 。 控制子系统提供疼痛减轻刺激子系统与心脏复律/除颤抗倒伏子系统的同步,以便在心脏复律/除颤反相之前开始向患者递送疼痛减轻刺激。
    • 4. 发明授权
    • Implantable cardioverter defibrillator having a smaller displacement
volume
    • 具有较小排量的植入式心律转复除颤器
    • US5697953A
    • 1997-12-16
    • US582529
    • 1996-01-11
    • Mark W. KrollTheodore P. AdamsKenneth M. AndersonCharles U. Smith
    • Mark W. KrollTheodore P. AdamsKenneth M. AndersonCharles U. Smith
    • A61N1/375A61N1/39H01M2/10H01M6/50H01M16/00
    • A61N1/375A61N1/3956A61N1/3758H01M16/00H01M2/1066H01M6/5016
    • A capacitor-discharge implantable cardioverter defibrillator (ICD) has a relatively longer device life of greater that 5 years. The longer life of the ICD is achieved by selecting and arranging the internal components of the ICD to deliver a maximum defibrillation countershock optimized in terms of a minimum physiologically effective current (I.sub.pe), rather than a minimum defibrillation threshold energy (DFT). As a result of the optimization in terms of a minimum effective current I.sub.pe, there is a significant decrease in the maximum electrical charge energy (E.sub.c) that must be stored by the capacitor of the ICD to less than about 30 Joules, even though a higher safety margin is provided for by the device. Due to this decrease in the maximum E.sub.c, as well as corollary decreases in the effective capacitance value required for the capacitor and the net energy storage required of the battery, the overall displacement volume of the ICD is reduced to the point where subcutaneous implantation of the device in the pectoral region of human patients is practical. The size of the capacitor is reduced because the effective capacitance required can be less than about 125 .mu.F. By optimizing both the charging time and the countershock duration for the smaller maximum E.sub.c, the size of the battery is reduced because the total energy storage capacity can be less than about 1.0 Amp-hours. In the preferred embodiment, the charging time for each defibrillation countershock is reduced to less than about 10 seconds and the pulse duration of the countershock is reduced to less than about 6 milliseconds.
    • 电容放电可植入式心律转复除颤器(ICD)具有相对较长的器件寿命,大于5年。 通过选择和布置ICD的内部组件来实现ICD的更长寿命,以提供根据最小生理有效电流(Ipe)而不是最小除颤阈值能量(DFT)优化的最大除颤抗倒伏。 作为最小有效电流Ipe优化的结果,ICD的电容器必须存储的最大电荷能量(Ec)显着降低到小于约30焦耳,即使较高的 设备提供安全余量。 由于最大Ec的这种减小以及电容器所需的有效电容值和电池所需的净能量存储的必然减小,ICD的总位移体积减少到皮下植入 在人类胸腔的器官是实用的。 电容器的尺寸减小,因为所需的有效电容可以小于约125μF。通过优化较小的最大Ec的充电时间和反冲时间,电池的尺寸减小,因为总能量存储容量 可以小于约1.0安培小时。 在优选实施例中,每个去纤维颤动反射的充电时间减少到小于约10秒,并且该反冲的脉冲持续时间减小到小于约6毫秒。
    • 7. 发明授权
    • Medical implant
    • 医疗植入
    • US4986831A
    • 1991-01-22
    • US186002
    • 1988-04-25
    • Wendell L. KingLawrence M. KaneTheodore P. Adams
    • Wendell L. KingLawrence M. KaneTheodore P. Adams
    • A61F2/00A61F2/06A61L27/08A61L27/14A61L27/16A61L27/18A61L27/50A61L31/04
    • A61L31/04A61F2/062A61L27/08A61L27/14A61L27/16A61L27/18A61L27/50A61F2310/00161
    • This invention is described and illustrated in connection with the generation of a homograft composed of collagenous tissue generated on a prosthetic device. A tubular substrate having generally cylindrical outside and inside surfaces is suspended in the lumen of a blood vessel of a living body. The tubular substrate is open at each end to permit blood to flow over both the inside and outside surfaces. One of the surfaces of the substrate is a thrombogenic surface or supports a thrombogenic mesh material to promote growth of a tube of collagenous tissue suitable for use as a surgical graft. The substrate is suspended in the blood flow of a blood vessel by an anchor which permits the substrate to freely move within the lumen of the vessel but is anchored by the tether to prevent the substrate from moving along the vessel in the direction of blood flow. The collagenous tissue growth about the substrate is generally tubular and suitable for use as a surgical graft.The method of generating a homograft includes preparing a prosthesis composed of a tubular substrate. The substrate is open at each end to permit blood to flow along the length of the substrate inside wall. The substrate is selected to have at least one thrombogenic surface or a thrombogenic mesh material supported by the substrate. The prosthesis is inserted in the lumen of a blood vessel, either a vein or artery, of a living body and anchored in the lumen of the vessel to prevent the substrate from moving along the vessel with the blood flow. The body generates collagenous growth on the thrombogenic surface of the substrate while the substrate is freely suspended in the blood flow of the vessel. The substrate is then removed from the vessel after which a tubular homograft of collagenous tissue is removed from the substrate.
    • 结合在假肢装置上产生的由胶原组织组成的同种移植物的产生来描述和说明本发明。 具有大致圆柱形的外表面和内表面的管状基底悬挂在生物体的血管的内腔中。 管状基底在每一端开放以允许血液流过内表面和外表面。 底物的一个表面是血栓形成表面或支持血栓形成网状物质,以促进适合用作手术移植物的胶原组织管的生长。 基底通过锚固体悬挂在血管的血流中,该锚固体允许基底在血管的内腔内自由移动,但是被系绳锚定,以防止基底沿血管沿血管方向移动。 围绕基底的胶原组织生长通常是管状的并且适合用作手术移植物。 产生同种移植物的方法包括制备由管状基质组成的假体。 基底在每一端开口以允许血液沿着基底内壁的长度流动。 衬底被选择为具有由衬底支撑的至少一个血栓形成表面或血栓形成网状物质。 将假体插入生物体的静脉或动脉的血管的内腔中并锚定在血管的内腔中,以防止基底沿着血管沿血管移动。 身体在衬底的血栓形成表面上产生胶原生长,同时衬底自由地悬挂在血管的血流中。 然后从容器中取出底物,然后从基质中除去胶原组织的管状同种移植物。